New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
09:11 EDTJNJJohnson & Johnson says has implemented some cost reductions in MD&D sector
Says has implemented some cost reductions, combined some businesses in the Medical Devices & Diagnostics sector to better compete in the current marketplace.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent JNJ news | >>
April 14, 2015
09:13 EDTJNJOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: JPMorgan Chase (JPM), up 1%... Johnson & Johnson (JNJ), up marginally... Triangle Petroleum (TPLM), up 4.2%... Fastenal (FAST), up 5%. ALSO HIGHER: Brainstorm Cell Therapeutics (BCLI), up 13.5% after announcing that it will present NurOwn Phase 2a clinical data at the Academy of Neurology annual meeting... Builders FirstSource (BLDR), up 7.2% after being upgraded to Buy from Hold at Stifel... Solazyme (SZYM), up 7.5% after announcing a strategic agreement with Flotek (FTK)... Cleveland BioLabs (CBLI), up 6.8% after receiving funding recommendation from the Department of Defense... Nordic American Tanker (NAT), up 3.2% after raising quarterly dividend to 38c from 22c... Ocwen (OCN), up 3.8% after reporting preliminary fiscal 2014 results. DOWN AFTER EARNINGS: Wells Fargo (WFC), down just under 1%. ALSO LOWER: Norfolk Southern (NSC), down 5.8% after being downgraded to Hold from Buy at TD Securities... RXi Pharmaceuticals (RXII), down 14.3% after filing to sell $20M of common stock and warrants... Arrowhead Research (ARWR), down 4.5% after being downgraded to Hold from Buy at Jefferies.
08:57 EDTJNJJohnson & Johnson backs FY15 sales $75B-$76B
Including foreign exchange, sees reported sales $70B-$71B. Consensus is $71.16B. Backs FY15 net interest expense $450M-$550M. Raises FY15 net other income expense to $2B-$2.1B from $1.5B-$1.6B. Expects R&D tax credit will be renewed by Congress. Raises FY15 effective tax rate to 21%-22% from 20%-21%. If the tax credit is not approved, it will negatively impact the tax rate by 0.5%. Comments taken from Q1 earnings conference call.
07:50 EDTJNJJohnson & Johnson reports Q1 Worldwide Consumer sales $3.4B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson cuts FY15 adjusted EPS to $6.04-$6.19 from $6.12-$6.27
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q1 domestic sales up 5.9% to $8.69B
Subscribe for More Information
07:45 EDTJNJJohnson & Johnson reports Q1 adjusted EPS $1.56, consensus $1.54
Subscribe for More Information
April 13, 2015
17:10 EDTJNJIBM establishes a Watson Health Cloud
Subscribe for More Information
16:21 EDTJNJOn The Fly: Top stock stories for Monday
Subscribe for More Information
15:38 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:08 EDTJNJJohnson & Johnson April 100 straddle priced for 2.2% movement into Q1
14:07 EDTJNJEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
13:28 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
11:12 EDTJNJJohnson & Johnson technical notes before earnings
Leading up to earnings, the shares have been trading in a narrow range largely bound by $98 at the low and $103 at the high. This trading range was preceded by a decline from the 52-week high set back in the fall of 2014. In a longer time frame, the current trading action is part of a larger potential topping process, with $95 as the midpoint. On worse than expected news, the low bound at $98 would be first important support. A breakdown below $98 would see next support at $95. A move below $95 would confirm the topping process and break the long-term uptrend. Support below $95 would be at $93.94. If results and outlook are better than expected, first resistance would be at the top of the range at $103. Next resistance would then be at $105.36. A move above that level would see $107.10, and then 52-week high and life high at $109.49 as next potential upside objectives.
April 10, 2015
14:39 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Johnson & Johnson April call option implied volatility is at 20, May is at 16, June is at 15, October is at 14; compared to its 26-week average of 16 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 14.
April 9, 2015
09:25 EDTJNJPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2015
09:23 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
07:24 EDTJNJNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
April 6, 2015
14:34 EDTJNJDepomed price target raised to $30 from $27 at Roth Capital
Subscribe for More Information
09:36 EDTJNJActive equity options trading on open
Subscribe for More Information
06:21 EDTJNJJohnson & Johnson CEO comments on Asia expansion, WSJ reports
Subscribe for More Information
1 | 2 | all recent JNJ news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use